Search Results

Your search for Javier Cort��s, MD,Javier Cort��s, MD matches 2 pages

Showing 1 - 2

By Matthew Stenger / Monday, January 11, 2016 9:30 AM

No Benefit Shown With Afatinib in HER2-Positive Breast Cancer With Progressive Brain Metastases

In the phase II LUX-Breast 3 trial reported in The Lancet Oncology, Cortés et al found that afatinib (Gilotrif) alone or combined with vinorelbine did not increase patient benefit vs investigator choice of treatment in patients with HER2-positive breast cancer and progressive brain...

breast cancer

By Caroline Helwick / Monday, September 29, 2014 11:38 AM

ESMO 2014: CLEOPATRA Study Shows ‘Unprecedented’ Survival With Dual HER2 Blockade in Metastatic Breast Cancer

In the final overall survival analysis of the phase III CLEOPATRA trial, patients with HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the ESMO 2014...

Jul

Today In Oncology

Search Results

Your search for Javier Cort��s, MD,Javier Cort��s, MD matches 2 pages

No Benefit Shown With Afatinib in HER2-Positive Breast Cancer With Progressive Brain Metastases

ESMO 2014: CLEOPATRA Study Shows ‘Unprecedented’ Survival With Dual HER2 Blockade in Metastatic Breast Cancer

Addition of Glofitamab to R-CHOP or Pola-R-CHP in Younger Patients With High-Risk LBCL

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

PPP2R1A Mutations Linked to Improved Immunotherapy Outcomes in Ovarian Clear Cell Carcinoma

Bevacizumab Plus Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer